Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study shows hope for the future of Tasmanian devils
Tasmanian devil
Devil facial tumour disease is a transmissible cancer that is spread by biting.

Animals show resistance to deadly facial cancer

Tasmanian devils have developed some genetic resistance to a devastating facial cancer that has plagued the species for 20 years.

Devil facial tumour disease (DFTD) has reduced the Tasmanian devil population by 80 per cent since it was first reported in 1996, and scientists predict that within decades it could wipe the species out altogether.

But new research shows that Tasmanian devils have developed some resistance to the disease in as little as four to six generations.  

In the study, published in Nature Communications, the team sampled 294 Tasmanian devils from three different populations. The samples were from before and after those groups encountered the disease.

They found that two of the genes, CD146 and THY1, were increasing in frequency throughout the devil populations and appeared to be helping their immune system to recognise foreign cells.

Speaking to BBC News, Dr Andrew Storfer from Washington State University, said this was cause for optimism.

"First and foremost, this gives us hope for the survival of the Tasmanian devil, which is predicted to be extinct but isn't," he said. "We see that the devils apparently are evolving genes that may be associated with resistance to the disease."

Dr Stormer, an evolutionary geneticist, was particularly excited at the speed at which the adaptions appeared to be happening.

"We're talking about roughly six generations in some populations, which is a very short period of evolutionary time."

DFTD is a transmissible cancer that is spread by biting and causes the appearance of tumours on the face or inside the mouth of affected individuals. The tumours are often very large and usually fatal.

The team say their research offers several avenues of hope for Tasmanian devil conservation, such as breeding programmes and vaccination studies. 

Image (C) KeresH/Wikimedia Commons 

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
Applications open for BEVA Back in the Saddle

The British Equine Veterinary Association (BEVA) has opened applications for its 'Back in the Saddle' coaching programme.

The online scheme offers structured group coaching for members wanting to reflect on their career path and regain clarity. Members may be returning to work after leave, uncertain about next steps or reassessing direction.

Attendees will benefit from impartial guidance and practical tools to support their professional development. Members are encouraged to take a 'proactive, future-focused approach' to their careers.

The sessions, taking place on Wednesdays from 7.30pm-9pm, are open to BEVA members with more than five years' experience. The first session takes place on Wednesday, 3 June 2026.

Applications will close on Wednesday, 27 May 2026.